Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Agios Pharmaceuticals’ dense clinical disclosures can feel like hunting for a single mutation in a genome. R&D expenses tied to pyruvate-kinase activators, FDA feedback on sickle-cell trials, and collaboration milestone payments sprawl across hundreds of pages. If you have ever asked, “How do I read the Agios Pharmaceuticals annual report 10-K simplified?” or searched for “Agios Pharmaceuticals insider trading Form 4 transactions,” you know the challenge.
Stock Titan’s AI-powered analysis turns that challenge into clarity. Our system ingests every 10-K, 10-Q, 8-K and S-1 the moment it hits EDGAR, then delivers plain-English summaries that highlight trial progress, cash runway and key risks—Agios Pharmaceuticals SEC filings explained simply. You can monitor Agios Pharmaceuticals Form 4 insider transactions real-time, receive alerts on Agios Pharmaceuticals quarterly earnings report 10-Q filing numbers, and access AI commentary that points to pivotal PK-activation data. Whether you need an Agios Pharmaceuticals earnings report filing analysis or a quick read on an Agios Pharmaceuticals 8-K material events explained, the insights are waiting.
Investors use this page to:
- Track Agios Pharmaceuticals executive stock transactions Form 4 before catalytic trial read-outs
- Compare period-over-period R&D spend without sifting through footnotes
- Review the Agios Pharmaceuticals proxy statement executive compensation for alignment with shareholder interests
- Gauge cash runway against pipeline timelines in seconds—understanding Agios Pharmaceuticals SEC documents with AI
James William Burns, Chief Legal Officer of Agios Pharmaceuticals (AGIO), reported significant insider transactions on June 24, 2025:
- Acquired 6,000 shares through the vesting of Performance Share Units (PSUs) at $0 exercise price
- Subsequently sold 2,799 shares at $33.54 per share to cover tax withholding obligations
- Following these transactions, Burns now directly owns 28,650 shares
The PSUs were originally granted on March 1, 2023, with 50% vesting upon achievement of a research milestone and 50% upon a regulatory milestone. The reported transaction reflects the vesting of the first 50% as the research milestone was met. The share sale was executed under a pre-established Rule 10b5-1 trading plan, providing an affirmative defense against insider trading liability.
Agios Pharmaceuticals (AGIO) Chief Medical Officer Sarah Gheuens reported significant insider transactions on June 24, 2025. The transactions involved performance share units (PSUs) and common stock:
- 6,000 PSUs converted to common stock upon achieving a specified research milestone
- 2,909 shares were automatically sold at $33.54 per share to cover tax obligations
- Following the transactions, Gheuens holds 56,988 shares directly
The PSUs were originally granted on March 1, 2023, with 50% vesting upon achievement of a research milestone (now met) and 50% contingent on a future regulatory milestone. The share sale was executed under a pre-established 10b5-1 trading plan, demonstrating compliance with insider trading regulations. This transaction suggests positive progress in the company's research initiatives, as evidenced by the milestone achievement triggering the PSU conversion.
Agios Pharmaceuticals (AGIO) Chief Financial Officer Cecilia Jones reported significant insider transactions on June 24, 2025. The transactions involved the vesting of performance share units (PSUs) and subsequent share disposals:
- Acquired 6,000 shares through the vesting of PSUs at $0 exercise price
- Sold 1,780 shares at $33.54 per share to cover tax withholding obligations
- Retained beneficial ownership of 30,049 shares following the transactions
The PSU vesting was triggered by achieving a specified research milestone, representing 50% of the original PSU grant from March 1, 2023. The remaining 50% will vest upon meeting a regulatory milestone. The share sale was executed under a pre-established Rule 10b5-1 trading plan, providing an affirmative defense against insider trading liability.
Agios Pharmaceuticals (AGIO) Chief Commercial Officer Tsveta Milanova reported significant insider transactions on June 24, 2025. The transactions involved performance share units (PSUs) and common stock:
- 6,000 PSUs converted to common stock upon achieving a specified research milestone, representing 50% of the total PSU grant from March 1, 2023
- 2,770 shares were subsequently sold at $33.54 per share to cover tax withholding obligations
- Following these transactions, Milanova holds 26,122 shares directly
The share sale was executed under a pre-established 10b5-1 trading plan. The remaining 50% of PSUs will vest upon achievement of a specified regulatory milestone. The transactions reflect standard executive compensation practices and planned tax-related sales rather than discretionary trading decisions.
Agios Pharmaceuticals (NASDAQ: AGIO) filed a Form 4 disclosing CEO Brian Goff’s June 24 2025 equity transactions.
- PSU vesting: 25,527 and 12,750 shares (total 38,277) converted to common stock at $0 cost.
- Automatic sales for tax-withholding: 12,471 and 6,229 shares sold at $33.54, generating roughly $0.63 million.
- Net change: Beneficial ownership rose by 19,577 shares to 111,922, a ~21 % increase versus the pre-vesting position.
- Sales executed under pre-arranged Rule 10b5-1 instructions; no discretionary selling.
The filing is routine and contains no operational, financial or strategic updates.
Agios Pharmaceuticals, Inc. – Form 144 filing
An unnamed insider intends to sell 1,761 common shares of Agios Pharmaceuticals, Inc. (AGIO) through Morgan Stanley Smith Barney on 24 June 2025. The shares, worth about $60,596, were obtained the same day via the vesting of restricted stock units. With 57.9 million shares outstanding, the proposed sale equates to roughly 0.003 % of total shares, indicating an immaterial ownership change. No other insider sales were reported in the past three months, and the filer certified that no undisclosed adverse information is known.
Agios Pharmaceuticals, Inc. (AGIO) has filed a Form 144 with the U.S. Securities and Exchange Commission disclosing a proposed insider sale under Rule 144.
- Shares to be sold: 1,761 shares of common stock
- Aggregate market value: $60,596
- Approximate sale date: 06/24/2025
- Broker: Morgan Stanley Smith Barney LLC, New York, NY
- Shares outstanding: 57,915,199
- Source of shares: Vesting of restricted stock on 06/24/2025
- Exchange: Nasdaq
The proposed sale represents roughly 0.003% of the company’s outstanding shares, indicating a de-minimis transaction that is unlikely to have a material effect on the company’s capital structure or market liquidity. No prior sales were reported in the past three months, and the filer attests to possessing no undisclosed material adverse information.
FAQ
What is the current stock price of Agios Pharmaceuticals (AGIO)?
What is the market cap of Agios Pharmaceuticals (AGIO)?
What is the primary focus of Agios Pharmaceuticals?
Which therapeutic areas does Agios target?
How does Agios Pharmaceuticals differentiate itself in the biopharmaceutical industry?
What is the significance of pyruvate kinase activation in their treatments?
What elements support Agios' expertise and trustworthiness?
What are some key clinical programs in the company’s pipeline?
How does Agios approach research and development?
How does Agios address the needs of patients with rare diseases?
